You are here: Industry Insights > Mesa Biotech

News List

Thermo Fisher Scientific Completes Mesa Biotech Acquisition contractpharma
March 02, 2021
Thermo Fisher Scientific Inc. has completed its acquisition of Mesa Biotech, Inc., a privately held point-of-care molecular diagnostic company.
Mesa Biotech Receives $13 Million from HHS to Develop 30 Minute SARS-CoV-2 & Flu A/Flu B Test americanpharmaceuticalreview
November 17, 2020
Mesa Biotech has been awarded a contract up to $13 million from the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the US Department of Health and Human ...
Mesa Biotech Receives Emergency Use Authorization for 30 Minute COVID-19 Test americanpharmaceuticalreview
March 26, 2020
Mesa Biotech announced it has received Emergency Use Authorization (EUA) from the U.S. Food & Drug Administration (FDA) for its Accula™ SARS-CoV-2 Test.
Mesa Biotech to Receive Funding from US Health and Human Services for Development of a 30 minute Molecular (PCR) Point-of-Care SARS-CoV-2 Test prnewswire
March 20, 2020
Mesa Biotech Inc., a privately-held, molecular diagnostic company has developed an affordable, 30 minute sample-to-answer molecular testing platform designed for point-of-care (POC) infectious disease diagnosis.
Mesa Biotech provides corporate update biospectrumasia
July 30, 2018
With a solid foundation, Mesa Biotech is well-positioned for continued progress in the second half of 2018. The company intends to invest recent funding in new assay development, increased production capacity, commercialization activities, facilities expa